Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ArtemiC in Patients Diagnosed With COVID-19
NCT04382040Phase 2Completed
- Sponsor
- MGC Pharmaceuticals
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of CimetrA in coronavirus disease 2019 (COVID-19), sponsored by MGC Pharmaceuticals. Started May 2020; status: completed.
02
Drugs
CimetrA
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04382040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382040.